Find policies, billing codes, payers, states, and providers
CPT 0024U: GlycA Glycosylated Acute Phase Protein Assay
CPT code 0024U designates a Proprietary Laboratory Analyses (PLA) test: the GlycA assay for glycosylated acute phase proteins, a blood-based measure of systemic inflammation developed by Laboratory Corporation of America. As a PLA code, 0024U identifies a single manufacturer-specific test and supports clear claims and tracking for this proprietary diagnostic. Nationally, PLA codes matter because they enable distinct coding for novel laboratory diagnostics that do not fit existing analyte codes, facilitating coverage determinations, utilization monitoring, and price transparency for emerging tests.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for GlycA testing, common sites of service and service type, and what to expect in payer engagement for a proprietary laboratory assay. The publication summarizes benchmark considerations, common billing modifiers, and practical coding notes relevant to billing and claims submission for 0024U. It also outlines where data were available and notes areas where specific payer policy details or utilization benchmarks are not provided. This national-level summary is intended for billing managers, laboratory administrators, and policy analysts seeking concise information on the coding and clinical role of the GlycA PLA test.
Customize your policy alerts
Sign up for cpt 0024U policy alerts
Get alerted when payer policies referencing 0024U are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 0024U is a Proprietary Laboratory Analyses (PLA) code that describes a single, manufacturer-specific laboratory test: the GlycA assay for glycosylated acute phase proteins, a biomarker of systemic inflammation, developed by Laboratory Corporation of America. The service type is laboratory diagnostic testing using a proprietary assay. The typical site of service is a clinical laboratory or reference laboratory setting where blood-based biomarker testing is processed.